A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT04322539. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Study identification
- NCT ID
- NCT04322539
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hutchison Medipharma Limited
- Industry
- Enrollment
- 691 participants
Conditions and interventions
Interventions
- Fruquintinib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 11, 2020
- Primary completion
- Jul 28, 2022
- Completion
- Apr 23, 2024
- Last update posted
- Apr 3, 2025
2020 – 2024
United States locations
- U.S. sites
- 45
- U.S. states
- 23
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| Arizona Oncology Associates, PC-HOPE | Tucson | Arizona | 85704 | — |
| California Research Institute (CRI) | Los Angeles | California | 90027 | — |
| City of Hope Comprehensive Cancer Center | Los Angeles | California | 91010 | — |
| Rocky Mountain Cancer Center | Aurora | Colorado | 80012 | — |
| The George Washington University Medical Center | Washington D.C. | District of Columbia | 20052 | — |
| Sarah Cannon Research Institute-S-Ft. Myers (FCS South) | Fort Myers | Florida | 33901 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| Cancer Care Centers of Brevard, Inc. | Palm Bay | Florida | 32901 | — |
| Sarah Cannon Research Institute-N-St Pete (FCS North) | St. Petersburg | Florida | 33705 | — |
| Sarah Cannon Research Institute-Pan-Tallahassee (FCS Panhandle) | Tallahassee | Florida | 32308 | — |
| Sarah Cannon Research-E-WPB (Florida Cancer Specialists-FCS East) | West Palm Beach | Florida | 33401 | — |
| Emory Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Affiliated Oncologists | Chicago Ridge | Illinois | 60415 | — |
| XCancer / Central Care Cancer Center | Garden City | Kansas | 67846 | — |
| University of Louisville - James Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Norton Cancer Institute Audubon | Louisville | Kentucky | 40217 | — |
| Hematology Oncology Clinic | Baton Rouge | Louisiana | 70809 | — |
| XCancer / Pontchartrain Cancer Center | Hammond | Louisiana | 70403 | — |
| Maryland Oncology Hematology, P.A. | Columbia | Maryland | 21044 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Minnesota Oncology | Minneapolis | Minnesota | 55404 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Center for Pharmaceutical Research | Kansas City | Missouri | 64114 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| XCancer / New Mexico Oncology & Hematology Consultants | Albuquerque | New Mexico | 87109 | — |
| Charleston Oncology | Charleston | South Carolina | 29414 | — |
| Sarah Cannon Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Vanderbilt Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Texas Oncology - Austin | Austin | Texas | 78705 | — |
| Texas Oncology Baylor Sammons | Dallas | Texas | 75246 | — |
| Texas Oncology-El Paso | El Paso | Texas | 79902 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology-McAllen | McAllen | Texas | 78503 | — |
| Texas Oncology-San Antonio | San Antonio | Texas | 78217 | — |
| Texas Oncology-Tyler | Tyler | Texas | 75702 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Providence Regional Cancer Partnership | Everett | Washington | 98201 | — |
| Northwest Cancer Specialists, P.C. | Vancouver | Washington | 98684 | — |
| Medical College of Wisconsin/ Froedtert Hospital | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 108 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04322539, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04322539 live on ClinicalTrials.gov.